Puma Biotechnology (PBYI) CFO sells shares under Rule 10b5-1 plan

Rhea-AI Filing Summary

Puma Biotechnology Chief Financial Officer Maximo F. Nougues reported two open-market sales of company common stock under a pre-arranged Rule 10b5-1(c) trading plan. On January 6, 2026, he sold 4,540 shares at a price of $5.844 per share, leaving him with 199,689 shares beneficially owned after that transaction. On January 7, 2026, he sold an additional 6,405 shares at $5.879 per share, resulting in 193,284 shares beneficially owned following the second sale. The filing notes that the referenced Rule 10b5-1 plan was adopted on December 14, 2020, indicating these sales were executed pursuant to that pre-established plan.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

NOUGUES MAXIMO F

(Last) (First) (Middle)

C/O PUMA BIOTECHNOLOGY, INC.

10880 WILSHIRE BLVD., SUITE 2150

(Street)

LOS ANGELES CA 90024

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PUMA BIOTECHNOLOGY, INC. [ PBYI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/06/2026		S(1)		4,540	D	$5.844	199,689	D
Common Stock	01/07/2026		S(1)		6,405	D	$5.879	193,284	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Adoption date of referenced 10b5-1(c) plan is: 12-14-2020

	/s/ Gordon Esplin as attorney-in-fact for Maximo F. Nougues	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did PUMA BIOTECHNOLOGY (PBYI) report in this Form 4?

The filing shows CFO Maximo F. Nougues sold company common stock in two transactions on January 6 and 7, 2026, and discloses his remaining share ownership after each sale.

How many PBYI shares did the CFO sell and at what prices?

On January 6, 2026, he sold 4,540 shares at $5.844 per share. On January 7, 2026, he sold 6,405 shares at $5.879 per share.

How many PBYI shares does the CFO hold after these transactions?

After the January 6, 2026 sale, he beneficially owned 199,689 shares. Following the January 7, 2026 sale, his beneficial ownership was 193,284 shares, held directly.

Were the PBYI CFO share sales under a Rule 10b5-1 trading plan?

Yes. The filing indicates the transactions were made pursuant to a Rule 10b5-1(c) trading plan, with an adoption date of December 14, 2020.

What is the role of the reporting person in PUMA BIOTECHNOLOGY (PBYI)?

The reporting person, Maximo F. Nougues, is identified as an officer of Puma Biotechnology, serving as its Chief Financial Officer.

Are these PBYI insider transactions direct or indirect holdings?

The Form 4 classifies the reported holdings and transactions as direct ownership, with no separate entity listed for indirect beneficial ownership.